Apheresis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:59 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Apheresis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Reducing Lipoprotein Apheresis with Pelacarsen in Patients with High Lipoprotein(a) and Heart Disease in Germany https://clinicaltrials.eu/trial/study-on-reducing-lipoprotein-apheresis-with-pelacarsen-in-patients-with-high-lipoproteina-and-heart-disease-in-germany/ Wed, 29 Apr 2026 14:29:59 +0000 https://clinicaltrials.eu/trial/study-on-reducing-lipoprotein-apheresis-with-pelacarsen-in-patients-with-high-lipoproteina-and-heart-disease-in-germany/ This clinical trial is focused on studying the effects of a treatment called pelacarsen (also known by its code name TQJ230) in patients with a condition known as hyperlipoproteinemia(a). This condition is characterized by high levels of a type of cholesterol called lipoprotein(a), which can lead to cardiovascular diseases such as heart attacks and strokes. Patients with this condition often undergo a procedure called lipoprotein apheresis, which is a process that removes lipoprotein(a) from the blood. The trial aims to see if pelacarsen can reduce the need for these apheresis sessions.

Participants in the study will receive either pelacarsen or a placebo, which is a substance with no active medication, through an injection. The study will last for 52 weeks, during which the frequency of lipoprotein apheresis sessions will be monitored. The goal is to determine if pelacarsen can decrease the number of apheresis sessions needed by patients, potentially improving their quality of life and reducing the burden of treatment.

The trial is designed to compare the effects of pelacarsen with those of a placebo in a controlled setting. By the end of the study, researchers hope to demonstrate that pelacarsen is more effective than the placebo in reducing the rate of lipoprotein apheresis sessions in patients with hyperlipoproteinemia(a) and established cardiovascular disease. This could lead to new treatment options for managing this condition and its associated health risks.

]]> Study on Long-Term Safety of Pelacarsen for Patients with Cardiovascular Disease Who Completed the Frontiers Apheresis Study https://clinicaltrials.eu/trial/study-on-long-term-safety-of-pelacarsen-for-patients-with-cardiovascular-disease-who-completed-the-frontiers-apheresis-study/ Wed, 29 Apr 2026 14:26:57 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-pelacarsen-for-patients-with-cardiovascular-disease-who-completed-the-frontiers-apheresis-study/ This clinical trial is focused on studying the long-term safety and tolerability of a treatment called pelacarsen, also known by its code name TQJ230. The study is specifically for patients with cardiovascular disease who have previously participated in a related study. Cardiovascular disease refers to conditions affecting the heart and blood vessels, which can lead to serious health issues like heart attacks or strokes. The treatment involves a solution for injection that is administered using a pre-filled syringe.

The purpose of this study is to evaluate how well patients tolerate the treatment over an extended period. Participants will receive the treatment through injections under the skin, known as subcutaneous use. The study will monitor any adverse effects or serious adverse events, as well as changes in laboratory evaluations and vital signs. The study will also track the number of lipoprotein apheresis sessions, a procedure that removes certain fats from the blood, performed each year for up to five years.

Throughout the study, the levels of a specific type of fat in the blood, known as Lp(a), will be measured at various intervals to see how they change compared to the start of the previous study. This will help researchers understand the long-term impact of pelacarsen on cardiovascular health. Participants in this study have already completed a prior study and are considered safe to continue by their healthcare provider. The study aims to provide valuable information on the safety of pelacarsen for individuals with cardiovascular disease.

]]>